Prostate Cancer Research Institute

PCRI is a 501(c) (3)
Not-for-profit public charity

Prostate Cancer Research Institute
  Donate    Helpline       Decision Aide     About Us      Español Sección en Español
   Events   Newsletter  PCRI Papers      Resources  Search

General Prostate Cancer News

PCRI is pleased to provide general prostate cancer news items courtesy of Inc. whose mission is “to empower patients with current information on all aspects of the management of Prostate Cancer in order to provide support and hope, as well as to facilitate informed decisions”.

Latest Prostate Cancer News

“Watchful Waiting” in Prostate Cancer Does Not Increase Anxiety (8/4/2009)
Men who choose to delay treatment for early prostate cancer do not experience increased anxiety from living with the disease, according to the results of a study published in Cancer.

Zometa® Reduces Bone Loss in Men with Prostate Cancer (7/23/2009)
A single infusion of Zometa® (zoledronic acid) upon initiation of androgen deprivation therapy for prostate cancer reduces bone mineral loss and maintains bone mineral density for 12 months, according to the results of a study published in Cancer.

False-positive Results Are Common with Cancer Screening (7/20/2009)
The risk of obtaining a false-positive result from screening for prostate, lung, colorectal, and ovarian cancer is high and becomes cumulatively higher with ongoing screening—after 14 screening tests, the cumulative risk of a false-positive is 60.4% for men and 48.8% for women, according to the results of a study published in the Annals of Family Medicine.

Diet and Exercise Intervention Produces Results in Long-term Survivors (7/14/2009)
Long-term survivors of breast, colorectal, and prostate cancer who participated in a year-long home-based diet and exercise intervention reported a smaller decline in physical function compared with their counterparts who did not participate in the program, according to the results of a study published in the Journal of the American Medical Association.

Long-term Androgen Suppression Is Superior for Prostate Cancer (6/22/2009)
Short-term androgen suppression produces inferior survival compared with long-term androgen suppression in the treatment of locally advanced prostate cancer, according to the results of a study published in the New England Journal of Medicine.

Copyright ©2005 All Rights Reserved.

General Prostate Cancer News Archives

Home    Site Map    About Us     Disclaimer     Contact

Prostate Cancer Research Institute (PCRI)


Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.